DiaMedica Therapeutics (DMAC) director granted 3,355-share RSU-based award

Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. director Semba Charles Pauling reported an equity-based compensation grant. On January 2, 2026, he acquired 3,355 shares of common stock at $8.42 per share, bringing his directly held stake to 47,963 shares.

The footnote explains that these shares are issuable upon settlement of restricted stock units granted under the company’s Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees totaling $28,250. The restricted stock units are scheduled to vest in four nearly equal installments on March 31, June 30, September 30, and December 31, 2026, meaning the director earns the related shares over the course of the year as service-based conditions are met.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Semba Charles Pauling

(Last) (First) (Middle)

301 CARLSON PARKWAY

SUITE 210

(Street)

MINNEAPOLIS MN 55305

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		3,355(1)	A	$8.42	47,963	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares are issuable upon settlement of restricted stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $28,250. The restricted stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026."

	/s/ Scott Kellen, attorney-in-fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed this Form 4 for DiaMedica Therapeutics (DMAC)?

The Form 4 was filed by Semba Charles Pauling, who is listed as a director of DiaMedica Therapeutics Inc. and is the sole reporting person on the form.

What transaction did Semba Charles Pauling report for DMAC on January 2, 2026?

He reported an acquisition (transaction code A) of 3,355 shares of common stock of DiaMedica Therapeutics Inc. on January 2, 2026, at a reported price of $8.42 per share.

How many DiaMedica Therapeutics shares does the director own after this Form 4 transaction?

Following the reported acquisition, Semba Charles Pauling is shown as beneficially owning 47,963 shares of DiaMedica Therapeutics Inc. common stock, held with direct ownership.

What is the nature of the equity award reported in this DMAC Form 4 filing?

The shares are issuable upon settlement of restricted stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, provided in lieu of cash retainer fees totaling $28,250.

What is the vesting schedule of the restricted stock units reported for DMAC?

The restricted stock units connected to the 3,355 shares are scheduled to vest in four nearly equal installments on March 31, June 30, September 30, and December 31, 2026.

Is the reported DMAC transaction a direct or indirect holding for the director?

The Form 4 indicates the ownership form for the reported shares as Direct (D), with no separate nature of indirect beneficial ownership listed.